Zacks.com on MSN2d
J&J Seeks FDA Nod for Non-Muscle Invasive Bladder Cancer Drug
Johnson & Johnson JNJ has initiated a rolling submission with the FDA seeking approval for TAR-200, its investigational ...
Science Daily3d
MRI scanning and biopsy could reduce delays in the correct treatment for bladder cancer by more than six weeks
Patients with a common aggressive type of bladder cancer could get correct treatment significantly quicker as new research suggests that initial MRI imaging and biopsy could be used to reduce the time ...
Targeted Oncology3d
FDA Considers TAR-200 in BCG-Unresponsive High-Risk NMIBC
An FDA application for TAR-200 to treat BCG-unresponsive high-risk non-muscle-invasive bladder cancer is under real-time ...
J&J Initiates Bid for FDA Approval of TAR-200 in Bladder Cancer
The New Brunswick, N.J., pharmaceutical giant said the FDA accepted the application through its Real-Time Oncology Review program, which allows for an earlier submission of topline efficacy and safety ...
Science Daily4d
Putting a lid on excess cholesterol to halt bladder cancer cell growth
Researchers discover novel targets for bladder cancer therapeutics and demonstrate that a new combination of existing drugs, including statins, blocks tumor growth in mice.
What are the symptoms of bladder cancer – and how is it treated?
Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...
Pfizer: My Top Play In 2025 Using Dogs Of The Dow Strategy
Pfizer is expected to rebound in 2025 with growth stabilized and dividend growth to continue. Learn why PFE stock is a Buy.